Methods of multi-indication meta-analysis for health technology assessment: A simulation study.

ABSTRACT: A growing number of oncology treatments, such as bevacizumab, are used across multiple indications. However, in health technology assessment (HTA), their clinical and cost-effectiveness are typically appraised within a single target indication. This approach excludes a broader evidence base across other indications. To address this, we explored multi-indication meta-analysis methods that share evidence across indications.We conducted a simulation study to evaluate alternative multi-indication synthesis models. This included univariate (mixture and non-mixture) methods synthesizing overall survival (OS) data and bivariate surrogacy models jointly modeling treatment effects on progression-free survival (PFS) and OS, pooling surrogacy parameters across indications. Simulated datasets were gen

SUBMITTER: Glynn D 

PROVIDER: S-EPMC12823204 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature